Vyome (HIND)
Develops topical therapies for inflammatory conditions and cancer-wound symptoms.
Something off on this page? Send us feedback.
Develops topical therapies for immuno-inflammatory and rare conditions, with antifungal product licensing in India and a clinical pipeline led by VT-1953; biotechnology economics depend on regulatory approval and subsequent commercialization, licensing, or partnering.
Develops topical therapies for immuno-inflammatory and rare conditions through its Biotechnology and Pharmaceutical Products segments. The clinical pipeline includes VT-1953 for symptoms of malignant fungating wounds, VT-1908 for anterior uveitis, and VB-1953 for inflammatory acne; the biotechnology candidates were unapproved in the latest annual filing.
Commercial activity centers on reformulated antifungal dandruff lotion and shampoo under licensing arrangements with Sun Pharmaceutical Industries in India. The corporate and investor-relations office is in Cambridge, Massachusetts, with an operating subsidiary in Delhi; the clinical pipeline is designed for US and global markets.
Uses US clinical and regulatory capabilities together with Indian science, medical talent, and cost structure. Biotechnology economics depend on regulatory approval and subsequent commercialization, licensing, or partnering, while VT-1953 is the primary capital-allocation priority.
Company facts
Categories
Target rangeAs of Sep 2, 2026
Latest analyst notes
| Date | Firm | Action | Target |
|---|---|---|---|
| Oct 2, 2025 | Maxim Group | Target | $15 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $7.9M · Total debt $17.3K · Total assets $9.2M · Shareholders' equity $6.0M
- Revenue
- $27.0K
- Operating income
- −$862.6K
- Net income
- −$685.6K
No dividends on record.
| Institutions12 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | ≈ 0.82% | 57.5K shares | |
| Insiders3 holders · as of Nov 18, 2025 | 6.49% | 455.2K shares | |
| Otherremainder | ≈ 92.69% | 6.51M shares |
7.02M company shares as of Sep 3, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Mohanjit JollyInsiderdirector | 6.48% | 454,456 | Form 4filed Nov 18, 2025 ↗ |
Geode Capital Management, LLCInstitution | 0.37% | 25,793 | 13Fas of Jun 30, 2026 |
Vanguard Fiduciary Trust CoInstitution | 0.17% | 12,195 | 13Fas of Jun 30, 2026 |
Susquehanna International Group, LLPInstitution | 0.14% | 10,058 | 13Fas of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 0.13% | 9,463 | 13Fas of Jun 30, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings · Form 4 — an insider's transaction report
Insider tradesForm 4
No open-market trades in the last 12 months.
- Smith & Nephew (ADR)
Advanced wound dressings are a substitute for topical MFW therapy.
- Bausch Health
Ortho Dermatologics' prescription topicals overlap in acne care.
- Kiora Pharmaceuticals
Clinical non-infectious-uveitis programs compete for development resources.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Vyome | $2.22 | +2.30% | $15.3M | — | — | 117.9 | −97.8% |
| Smith & Nephew (ADR) | $28.58 | −0.34% | $12.04B | 19.0 | — | 1.9 | +3.7% |
| Bausch Health | $6.82 | −0.07% | $2.55B | — | 1.5 | 0.2 | +11.2% |
| Kiora Pharmaceuticals | $2.58 | +2.79% | $11.5M | — | — | — | — |
| Median | 19.0 | 1.5 | 1.1 | +7.5% |